The influence of dosage form on aspirin kinetics: Implications for acute cardiovascular use

Current Medical Research and Opinion

Volumn 13, Issue 10, 1997, Pages 547-553

  Muir, N ^a   Nichols, J D ^a   Clifford, J M ^a   Stillings, M R ^a   Hoare, R C ^a  

^a Reckitt & Colman   (United Kingdom)

Author keywords

Aspirin; Myocardial infarction; Pharmacokinetics; Solubility; Speed of action

Indexed keywords

ACETYLSALICYLIC ACID; ACETYLSALICYLIC ACID CALCIUM;

ADULT; ARTICLE; BLOOD SAMPLING; CARDIOVASCULAR SYSTEM; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG FORMULATION; DRUG HALF LIFE; DRUG INDICATION; DRUG USE; ENTERIC COATED TABLET; HEART INFARCTION; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; RANDOMIZED CONTROLLED TRIAL;

EID: 0030826569     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/03007999709113328     Document Type: Article

References (20)

1. Anti-platelet Trialists Collaboration. (1994). Collaborative overview of randomised controlled trials of antiplatelet therapy - I: Prevention of death, myocardial infarction and stroke by prolonged antiplatelet therapy in various categories of patients. Br. Med. J., 308, 81-106.
2. Flapan, A. D., (1994). Management of patients after their first myocardial infarction. Br. Med. J., 309, 1129-1134.
3. NHS Centre for Reviews and Dissemination, (1995). Aspirin as emergency therapy, Effectiveness Matters, 1, 1-4.
4. East Norfolk Health Commission, (1995). Guidelines for Practice Procedure with a Suspected Heart Attack.
5. Weston, C. F. M., Penny, W. J., and Julian, D. G., (1994). British Heart Foundation Working Party. Guidelines for the early management of patients with MI. Br. Med. J., 308, 760-761.
6. Pentecost, G., (1994), Myocardial infarction. Update, May, 816-821.
7. Rasmanis, G., Vestequist, O., Green, K., Edhag, O., and Henriksson, P., (1992). Evidence of increased platelet activation after thrombolysis in patients with acute myocardial infarction. Br. Heart J., 68, 374-376.
8. Fitzgerald, D. J., Catella, F., Roy, L., and Fitzgerald, G. A., (1988). Marked platelet activation in vivo after intravenous streptokinase in patients with acute myocardial infarction. Circulation, 77, 142-150.
9. Rudd, M. A., George, D., Amarante, P., Vaughan, D. E., and Loscalzo, J., (1990). Temporal effects of thrombolytic agents on platelet function in vivo and their modulation by prostaglandins. Circ. Res., 67, 1175-1181.
10. Reckitt and Colman, (1983). Data on file.
11. Cochran, W. G., and Cox, G. M., (1957). Completely randomised, randomised block or Latin square designs. In Stewhart, W. A. and Wilks, S. S. (Eds), Experimental Designs, 2nd edn, Wiley.
12. Hartley, H. O., (1955). Some recent developments in analysis of variance. Comm. Pure App. Math., 8, 47-72
13. Siegel, S., and Castellan, N. J., (1988), In Morgan C. T. (Ed.), Non-parametric Statistics for the Behavioural Sciences, 2nd edn, McGraw-Hill.
14. Muir, N., Nichols, J. D., Stillings, M. R., and Sykes, J., (1997). Comparative bioavailability of aspirin and paracetamol following single dose administration of soluble and plain tablets. Curr. Med. Res. Opin., 13, 491-500.
15. ISIS-2 (Second International Study of Infarct Survival), (1988). Randomised trial of intravenous streptokinase, oral aspirin, both or neither among 17,871 cases of suspected acute myocardial infarction. Lancet, ii, 349-360.
16. Shaw, P., (1992). Evidence now clear that aspirin will reduce heart and stroke deaths. Australian Doctor Weekly, August, 19.
17. Aumiller, J. (Ed.), (1991). Aspirin Newsletter Congress Special.
18. Dabaghi, S. F., Kamat, S. G., Payne, J., Markes, G. F., Roberts, R., Schafer, A. I., and Kleinman, N. S., (1994). Effects of low-dose aspirin on in-vitro platelet aggregation in the early minutes after ingestion in normal subjects. Am. J. Cardiol., 74, 720-723.
19. Zhang, C. L., Wilson, K. M., Stafford, I., Bochner, F., and Horowitz, J. D., (1994). Absorption kinetics of low dose aspirin in patients with evolving acute myocardial infarction. Drug Invest., 1, 169-174.
20. Elwood, P., (1997). Letter, Lancet, 349, 432.